NEURIZON THERAPEUTICS

Neurizon has appointed Justine Conway, head of global business development at Elanco, as an observer on its supervisory board. The appointment follows the exclusive global licensing agreement for monepantel (active ingredient in NUZ-001) and is intended to secure access to animal safety and manufacturing data for clinical studies and regulatory approvals. Conway brings more than 20 years of experience in animal health, investment banking and M&A and will attend meetings without voting rights, while Neurizon advances late-stage development of NUZ-001 and plans to participate in the HEALEY-ALS platform study. » More on de.investing.com